Loading...
•
Sep 30, 2022
Replimune Q2 2023 Earnings Report
Reported financial results for the fiscal second quarter and provided a business update.
Key Takeaways
Replimune Group announced financial results for the fiscal second quarter ended September 30, 2022. The company is focused on establishing oncolytic immunotherapies as a cornerstone treatment for solid tumor indications and plans to establish a major skin cancer franchise with RP1. They completed a $200 million term-loan that extended cash runway into 2025.
Completed enrollment in the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023.
Six-month follow-up data from the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® (nivolumab) in anti-PD1 failed melanoma expected by year end.
An update on the RP2/3 development program remains on track to be provided by year end.
Completed $200 million term-loan that extended cash runway into 2025.
Replimune
Replimune
Forward Guidance
The Company believes that existing cash, cash equivalents and short-term investments, as of September 30, 2022, together with unrestricted proceeds available to be drawn under the Hercules debt facility, will enable funding operations into calendar 2025.